On the heels of the announcement about the CE mark for Euformatics’ omnomicsNGS tool for genome variant interpretation, Christophe addresses the challenges of building a business around clinical usage of NGS data in an interview with GenomeWeb. The interpretation of gene variants has opened multiple avenues for personalised medicine. Also regular control of quality all along the NGS workflow, from the sequencer, via the capture kits, all the way to bioinformatics treatment of the data is of fundamental importance, as documented in CAP and EuroGentest best practice guidelines. The burgeoning role of standardising NGS data quality also offers opportunities for collaborations between clinical service providers, academic researchers, and the bio-IT industry.